979例抗肿瘤药物不良反应分析

doi:10.5246/jcps.2025.03.017

中国药学(英文版) ›› 2025, Vol. 34 ›› Issue (3): 223-231.DOI: 10.5246/jcps.2025.03.017

979例抗肿瘤药物不良反应分析

徐兴农¹^,², 何豆豆², 马磊¹^,^*()

^1. 华东理工大学药学院, 上海 200237
^2. 盐城市第三人民医院药学部, 江苏盐城 224000

收稿日期:2024-11-15 修回日期:2024-12-05 接受日期:2025-01-06 出版日期:2025-03-31 发布日期:2025-04-01
通讯作者: 马磊

Analysis of 979 cases of adverse drug reactions induced by antineoplastic drugs

Xingnong Xu¹^,², Doudou He², Lei Ma¹^,^*()

¹ School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
² Department of Pharmacy, Yancheng Third People's Hospital, Yancheng 224000, Jiangsu, China

Received:2024-11-15 Revised:2024-12-05 Accepted:2025-01-06 Online:2025-03-31 Published:2025-04-01
Contact: Lei Ma
Supported by:
Collaborative Innovation Program of Jiangsu Pharmaceutical Vocational College (Grant No. 20239120).

摘要/Abstract

摘要：

本研究分析抗肿瘤药物的不良反应(adverse drug reaction, ADR)的特征与规律, 为患者化疗安全用药提供参考。收集2022年1月1日至 2023年12月31日我院979例抗肿瘤药物ADR报告, 并对报告数据进行统计和分析。979例抗肿瘤药物ADR报告中72.73%发生在医院内, 男性患者的ADR发生率低于女性, 年龄分布以51~70岁为主(59.14%)。静脉滴注是引发ADR的主要给药途径(69.66%), 严重ADR占9.30%, 1例经停药或治疗未好转。细胞毒类抗肿瘤药物的ADR占97.85%, 其中以奥沙利铂最常见(19.82%)。ADR主要累及胃肠系统(60.79%)。应加强细胞毒类抗肿瘤药特别是铂类ADR的监测, 在化疗使用抗肿瘤药物时应评估ADR风险并制定相应治疗方案, 确保患者用药安全。

关键词: 抗肿瘤药物, 不良反应, 用药安全

Abstract:

The aim of this study is to evaluate the characteristics and patterns of adverse drug reactions (ADRs) associated with antineoplastic drugs and provide insights for safer chemotherapy practices. Based on 979 ADR cases reported in our hospital from January 1, 2022, to December 31, 2023, an analysis was conducted. Statistical analysis of the data revealed that 72.73% of these ADR incidents occurred in a hospital setting. The incidence of ADRs was higher in female patients compared to males, with the majority of cases (59.14%) observed in individuals aged 51–70 years. Intravenous administration was the predominant route linked to ADRs, accounting for 69.66% of the cases. Serious ADRs represented 9.30% of the total, including one instance where symptoms did not improve despite drug discontinuation or treatment. Cytotoxic antineoplastic drugs were responsible for 97.85% of all ADRs, with oxaliplatin being the most frequently implicated agent (19.82%). Gastrointestinal system involvement was the most common ADR manifestation, observed in 60.79% of cases. These findings underscored the necessity of enhanced monitoring for ADRs associated with cytotoxic antineoplastic drugs, particularly platinum-based agents. Comprehensive risk assessments and tailored treatment plans should be implemented during chemotherapy to minimize the occurrence of ADRs and safeguard patient safety.

Key words: Anti-tumor drugs, Adverse effects, Drug safety

Supporting:

徐兴农, 何豆豆, 马磊. 979例抗肿瘤药物不良反应分析[J]. 中国药学(英文版), 2025, 34(3): 223-231.

Xingnong Xu, Doudou He, Lei Ma. Analysis of 979 cases of adverse drug reactions induced by antineoplastic drugs[J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(3): 223-231.

图/表 5

Table 1. Gender and age distribution of patients.

Table 2. Types of antineoplastic drugs causing ADRs.

Table 3. System-organ involvement and clinical manifestations of ADRs.

Table 4. Time of occurrence of ADR.

Table 5. Time distribution for ADR regression outcomes: improvement or recovery.

参考文献 16

[1]	Han, B.F.; Zheng, R.S.; Zeng, H.M.; Wang, S.M.; Sun, K.X.; Chen, R.; Li, L.; Wei, W.Q.; He, J. Cancer incidence and mortality in China, 2022. J. Natl. Cancer Cent. 2024, 4, 47–53.
[2]	Cao, W.; Chen, H.D.; Yu, Y.W.; Li, N.; Chen, W.Q. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin. Med. J. 2021, 134, 783–791.
[3]	Huang, H.J.; Mai, J.H.; Zhang, Y.H.; Guo, C.C; Liang, W.T. Adverse drug reaction induced by antineoplastic drugs in a cancer hospital: an analysis of 613 cases. Chin. J. Pharmacovigil. 2024, 21, 324–330, 334.
[4]	Xiao, H.T.; Li, G.H. Guidelines for the clinical application of new anticancer drugs (2023 Edition). Vol 1. 6th ed. Beijing: People’s Health Publishing House. 2023, 13.
[5]	Park, J.Y. Analysis of data on capecitabine-related adverse drug reactions from the Korean adverse event reporting system database. Eur. J. Oncol. Nurs. 2018, 34, 55–60.
[6]	Wahlang, J.B.; Laishram, P.D.; Brahma, D.K.; Sarkar, C.; Lahon, J.; Nongkynrih, B.S. Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital. Ther. Adv. Drug Saf. 2017, 8, 61–66.
[7]	Zheng, S.Z.; Liu, L.L.; Li, G.R. Retrospective analysis of adverse drug reactions between 2018 and 2022 in a tertiary general hospital. J. Guangdong. Med. Coll. 2023, 41, 685–689.
[8]	Feng, S.Y.; Chen, P.J.; Wang, N.; Zhao, B.; Lu, Y.F.; Zhang, Y.H. Exploration of collaborative drug therapy management mode for elderly patients with chronic diseases. J. Chin. Pharm. Sci. 2022, 31, 866–876.
[9]	Katsura, C.; Ogunmwonyi, I.; Kankam, H.K.; Saha, S. Breast cancer: presentation, investigation and management. Br. J. Hosp. Med. (Lond). 2022, 83, 1–7.
[10]	Zhao, Y.W.; Wang, L.L.; Shi, Y.H. A study of adverse reactions to platinum-based antineoplastic drugs in a hospital. J. Chin. Med. 2022, 12, 84–88.
[11]	Huo, J.Y.; Wang, N.N.; Li, X.M.; Zhang, Y.H.; Han, Y. Analysis of adverse drug reactions and risk factors of anticancer chinese medicine. J. Chin. Pharm. 2023, 32, 120–123.
[12]	Tang, L.N.; Zhou, X.W.; Dong, L.L.; Wang, M.Y.; Wei, Y.X.; Zhang, Y.X. Analysis of 533 cases of adverse drug reactions induced by antineoplastic drugs. Anti-tumor Pharmcy. 2022, 12, 663–670.
[13]	Xu, W.J.; Gao, Y.; Ye, M.L.; Cai, L. Analysis of 346 adverse drug reactions reports associated with antineoplastic drugs in a tertiary class A hospital. Chin. J. Drug Appl. Monitor. 2020, 17, 104–107.
[14]	Liu, Q.Y.; He, F.; Shen, L. Analysis of Utilization of antitumor drug in 172 patients with Lung Cancer in a hospital. J. Dali. Univ. 2022, 7, 28–31.
[15]	Xu, W.J.; Chen, N.; Zeng, J.C. Literature analysis of adverse reactions related to bevacizumab. Mod. Drugs. Clin. 2022, 37, 415–419.
[16]	Li, C.X.; Wang, D.; Mo, T.X; Wang, Y.; Sun, H. Study on the current situation of daycare chemotherapy in China. Chin. Hosp. Manag. 2022, 42, 47–49.

979例抗肿瘤药物不良反应分析

Analysis of 979 cases of adverse drug reactions induced by antineoplastic drugs

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 5

参考文献 16

相关文章 13

编辑推荐

Metrics

本文评价

[1]	孙雪林, 张亚同, 钱东方, 谭斯元, 张子轩, 金鹏飞, 胡欣. 中国药品上市后信号检测现状调查: 一项基于访谈的研究[J]. 中国药学(英文版), 2025, 34(2): 175-184.
[2]	涂颖秋, 赖敏芳, 钟楠, 曹洪晓, 黄正刚. 13岁以下儿童使用泊沙康唑口服混悬液的真实世界安全性研究[J]. 中国药学(英文版), 2024, 33(4): 352-357.
[3]	左靖, 孟珺, 李超, 夏铮铮, 唐浩淳, 李安娜, 马晓芙. UGT1A1杂合突变与伊立替康所致不良反应的真实世界研究[J]. 中国药学(英文版), 2024, 33(1): 35-45.
[4]	常馨予, 韩丽娟, 刘洋, 范峥, 吴剑坤. 碳青霉烯类药物致血小板不良反应分析及相关文献回顾[J]. 中国药学(英文版), 2023, 32(10): 835-841.
[5]	裴彦宇, 郝继晖, 段文琪, 郑宇静, 赵明, 杨莉萍. 利奈唑胺严重与致死性不良反应——案例报道的汇总分析[J]. 中国药学(英文版), 2022, 31(2): 153-161.
[6]	曹晶晶, 孙俊, 赵淑娟, 马培志. 流感新药巴洛沙韦的药理作用及临床评价[J]. 中国药学(英文版), 2020, 29(10): 729-733.
[7]	邵淑容, 郭卫. 静脉注射人免疫球蛋白临床应用的不良反应之三年回顾性研究[J]. 中国药学(英文版), 2019, 28(1): 56-61.
[8]	余维纳, 熊有毅, 陈卓, 王芳. α-1酸性糖蛋白预测多西他赛副作用在乳腺癌患者中的应用[J]. 中国药学(英文版), 2017, 26(12): 895-899.
[9]	朱刚直, 易勤, 范志宏, 马岳慧, 王丹丹, 王磊, 程泽能. LC-MS/MS法测定大鼠血浆中PAC-1的新型抗癌衍生物的浓度及其药物动力学研究[J]. 中国药学(英文版), 2017, 26(11): 811-818.
[10]	薛清丹, 鞠爱霞, 康宇红, 郑春雨, 李秋红. 甲基莲心碱对阿霉素药动学影响[J]. 中国药学(英文版), 2015, 24(4): 225-230.
[11]	魏艳红, 杨莉萍, 张亚同, 邵宏. 心律失常患者使用噻托溴铵粉吸入剂引起房颤1例[J]. 中国药学(英文版), 2015, 24(3): 192-194.
[12]	罗晓, 邵宏. 伊曲康唑治疗EICU侵袭性真菌感染的疗效与安全性分析[J]. 中国药学(英文版), 2015, 24(10): 678-682.
[13]	贺飞, 黄卉, 尹富玲, 李润涛, 雷小平, 曾慧慧^*. 新型DTC金属配合物的抗肿瘤活性及构像研究[J]. , 2005, 14(4): 213-216.